Editorial board member Nicola A Hanania (Baylor College of Medicine, TX, US) considers the role of biologics in the management of asthma and chronic obstructive pulmonary disease (COPD).
Questions
1. What have been the most promising advances in molecular phenotyping of asthma and chronic obstructive pulmonary disease (COPD)? (0:12)
2. How are selective blood biomarkers being used to inform therapeutic decisions in COPD and asthma patients? (1:33)
3. What are the advantages and limitations of the new biologic therapies in severe asthma and COPD? (2:50)
4. What is the role of macrolides in the treatment paradigm of severe asthma and COPD? (5:14)
5. What do you see as the remaining unmet needs in this area? (6:47)
Speaker disclosure: Nicola A Hanania has received honoraria for serving on advisory boards or as a consultant for Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Novartis, and Sanofi/Regeneron. His institution has received research grant support on his behalf from Boehringer Ingelheim, AstraZeneca, Roche, and GlaxoSmithKline.
Filmed at the European Respiratory Society (ERS) International Congress 2018, Paris, France, September 2018.
